Drug Screening Using IMD in Bladder Cancer

Drug Screening Using IMD in Bladder Cancer
Conditions: Muscle Invasive Bladder Urothelial Carcinoma

Interventions: Device: Implantable Micro-Device; Drug: Methotrexate; Drug: Carboplatin; Drug: Avelumab; Drug: Paclitaxel; Drug: Vinblastine; Drug: Gemcitabine/Cisplatin I; Drug: Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab; Drug: Gemcitabine/Cisplatin II; Drug: Cisplatin; Drug: Nivolumab; Drug: Pembrolizumab; Drug: Gemcitabine/Carboplatin; Drug: Methotrexate/Vinblastine/Doxorubicin/Cisplatin; Drug: Gemcitabine/Cisplatin/Nivolumab; Drug: Erdafitinib; Drug: Paclitaxel/Docetaxel/Ifosfamide; Drug: Gemcitabine; Drug: Gemcitabine/Carboplatin/Nivolumab; Drug: Enfortumab; Drug: Sacituzumab

Sponsors: Brigham and Women’s Hospital


Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 13, 2024Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine